EU Panel Backs Venetoclax/Rituximab Combo in Relapsed/Refractory CLL

September 21, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) is supporting the approval of venetoclax in combination with rituximab for patients with chronic lymphocytic leukemia (CLL) who have received at least 1 previous therapy. AbbVie, who is a co-developer of venetoclax with Roche, announced the CHMP’s decision in a news release. “The venetoclax-plus-rituximab combination has the potential to be … (leggi tutto)